Early access programme services
EAPs can shorten timelines and create a strong foundation for European success
Expanding into Europe comes with unique challenges – diverse regulations, cultural nuances and significant risks. Before full regulatory approval or whilst awaiting local reimbursement decisions, companies need pathways that accelerate medicines to patients whilst gathering evidence to maximise commercial success and demonstrate value to regulators and payers.
Sciensus’ regulatory, distribution and patient engagement expertise enables faster, compliant market access through early access programmes. EAPs provide real-world evidence that strengthens HTA submissions and builds trust before pricing discussions, whilst allowing companies to validate operational readiness and execute a flawless European launch in a controlled setting.
Faster patient access to treatments
Real-world evidence to support regulatory and payer decisions
Smarter launch planning and commercial advantage
Faster access to patients in Europe
The drug development process is long and fragmented, unique European healthcare and regulatory systems can add even more time to the process. Sciensus can accelerate your access to patients through a turn-key EAP programme. Leveraging over 30 years of experience across Europe, including six EAPs in 12 countries, Sciensus can identify the right patients, deliver drug and engage patients in their care, ensuring that your therapy is accelerated to patients who need it and that you can gather the critical insights needed to fuel your full commercialisation process.
-
Regulatory expertise and market access
-
End-to-end programme delivery
-
Patient access and evidence generation
Ready to expand access without regulatory headaches?
Get in touch to discover how our local expertise and pan-European infrastructure handle the complexity, so you can focus on patients
Expanded access programme vs. clinical trials
Clinical trials for rare diseases and complex speciality therapies can face practical challenges, including limited patient populations, restrictive eligibility criteria and lengthy development timelines. Early access programmes help address these gaps by making promising therapies available to patients with serious conditions who may not be able to participate in a clinical trial.
Unlike clinical trials, early access programmes:
- Typically allow broader patient populations to access treatment
- Reflect routine clinical practice and real-world patient experiences
- Generate real-world data on treatment use, safety and patient outcomes in everyday care settings
These insights complement clinical trial findings by helping pharmaceutical companies understand how therapies perform across a wider patient population and healthcare environment.
Through the Sciensus Axcess Portal and broader patient engagement infrastructure, programme data can be captured and analysed to support regulatory, market access and commercial decision-making.
Demonstrated success in unlocking Europe
Established European relationships
Global reach, local expertise
Frequently asked questions
What is an Early Access Programme (EAP)?
An Early Access Programme allows patients with serious or life-threatening conditions to access a medicine before it becomes commercially available or fully reimbursed in their country. EAPs can operate through different mechanisms depending on local regulations, including Compassionate Use Programmes, Managed Access Programmes and Named Patient Programmes.
When should a company consider launching an EAP?
Many companies begin planning EAPs during late-stage clinical development, often around Phase III, although programmes can be introduced both before and after regulatory approval depending on strategic objectives, patient need and local market conditions.
What are the benefits of an EAP for pharmaceutical companies?
An EAP can help companies provide treatment access to patients with unmet need, gather real-world evidence, build relationships with key prescribers, improve launch readiness and generate insights that support pricing, reimbursement and commercial planning.
What data can be collected through an EAP?
Depending on programme design and local regulations, EAPs can generate real-world data on patient populations, treatment utilisation, safety, effectiveness, outcomes and patient experience. This information can help strengthen future market access and reimbursement discussions.
Can EAP data be used to support reimbursement and HTA submissions?
Real-world evidence generated through an EAP can complement clinical trial data by demonstrating how a medicine performs in routine clinical practice. This may help support HTA submissions, payer discussions and reimbursement negotiations.
Which countries in Europe support Early Access Programmes?
Early access regulations vary by country. Some countries have formal national frameworks while others operate through alternative mechanisms such as Named Patient Programmes. Each market has its own regulatory requirements, timelines and compliance obligations.
What are the biggest challenges when running an EAP?
Common challenges include navigating multiple regulatory frameworks, maintaining product supply, managing pharmacovigilance obligations, collecting consistent data across countries and aligning the programme with future commercial launch plans.
How does an EAP support a successful commercial launch?
EAPs provide insight into patient demand, treatment pathways, prescriber behaviour and operational requirements before launch. This helps companies refine market access strategies, prepare for reimbursement discussions and improve launch execution.
Can an EAP be combined with patient support services?
Yes. Support services can be integrated around an EAP to help patients access, understand and remain on treatment while generating insights that support long-term commercialisation and evidence generation objectives.
What support does Sciensus provide for EAPs?
Sciensus supports programme design, regulatory navigation, supply chain management, patient access, pharmacovigilance, real-world data collection and commercial launch preparation across multiple European markets.
Meet our early access programme expert
Get in touch
Thank you for your interest in Sciensus. Whether you’re seeking information, partnership opportunities, or want to refer a patient, our dedicated team is here to assist you. Please fill out the form on the right, and one of our multi-lingual representatives will get in touch with you promptly.